University of California

Other

Nevagen LLC

Maurizio Zanetti

Daniel J Kroon

Petar Lenert

Edward Golub

Maurizio Sollazzo

Provided are engineered B lymphocytes modified to express one or several different types of microRNAs or anti-miRs where in one embodiments the lymphocytes contain multiple copy numbers of nucleic acids encoding the one or several different types of miRs or anti-miRs. Provided are compositions and methods for treating, ameliorating, or preventing a cancer cell, a breast cancer cell or a triple negative breast cancer, or a breast cancer cell that tests negative for estrogen receptors, progesterone receptors, or HER2, comprising or by administering a composition, formulation or pharmaceutical composition comprising a microRNA or anti-miR. Provided are methods for treating an inflammation, a disease, a condition, infection or cancer capable of being treated by modulation or inhibition or expression of an miRNA or anti-miRs by administering to an individual in need thereof a B lymphocyte that secretes a microRNA or anti-miR, or a B lymphocyte supernatant, extracellular vesicle or exosome having a microRNA or anti-miR.

Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them

Described herein are compositions of matter and methods for treating cancer. The compositions comprise altered human telomerase polypeptides containing T cell epitopes that have been altered to increase immunogenicity. The methods comprise administration of the polypeptides or nucleic acids, such as DNA or RNA encoding the polypeptides, to individuals afflicted with, or at risk of, developing cancer.

Universal cancer vaccine

Telomerase peptides that bind MHC are disclosed. The instant application also discloses vaccines containing said peptides and methods of using said peptides to enhance a CTL response against mammalian cancer cells.

Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response

The invention provides a method for stimulating an immune response by administering to a lymphoid tissue a nucleic acid molecule comprising an expression element operationally linked to a nucleic acid sequence encoding one or more heterologous epitopes. The heterologous epitope can be inserted into a complementarity-determining region of an immunoglobulin molecule. The invention also provides a nucleic acid molecule comprising a hematopoietic expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide. The invention additionally provides a method of treating a condition by administering a nucleic acid molecule comprising a hematopoietic cell expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide, wherein the nucleic acid molecule is targeted to a hematopoietic cell.

Somatic transgene immunization and related methods

DNA molecules, expression vectors, recombinant host cells and the process of preparing antigenized antibodies which have, inserted within their third complementarity determining regions, antigenic epitopes not found in immunoglobulin molecules are described.

DNA molecules, expression vectors and host cells expressing antigenized

Antigenized antibodies which have inserted within their third complementarity determining regions, antigenic epitopes not found in immunoglobulins are described.

Antigenized antibodies and genes

Antibodies have been recombinantly produced which contain the NANP tetrapeptide of Plasmodium Falciparum within their third complementarity determining region in N-terminus of the variable region. These antibodies are capable of eliciting an antibody response.

A method of separating V.sub.H containing immunoglobulins by admixing an immunoglobulin binding peptide is described. The polypeptide of the invention is capable of binding to heavy chain variable regions of antibodies in an antigen independent manner and can separate antigen/antibody complexes.

Immunoglobulin-binding polypeptides

Polypeptides having a segment capable of binding to immunoglobulin heavy chain variable regions (V.sub.H) in an antigen independent manner have been described. These polypeptides can be used to form complexes with V.sub.M containing molecules for diagnostic purposes and to increase the affinity of the antibody for its antigen. Additionally, the polypeptides of the invention can be used to separate V.sub.H containing molecules from solution to form isolated V.sub.H or V.sub.H depleted compositions.

Growing community of inventors

La Jolla, CA, United States of America

Maurizio Zanetti